+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Services and Technologies - Distribution by Type of Lipid Nanoparticle, Type of Molecule Delivered, Company Size, Target Therapeutic Area, Type of End-user and Key Geographical Regions

  • PDF Icon

    Report

  • 290 Pages
  • December 2023
  • Region: Global
  • Roots Analysis
  • ID: 5917605

Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs

The global lipid nanoparticle manufacturing market is estimated to be worth USD 0.66 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 11.8% during the forecast period 2023-2035.

Over the past few years, there has been a substantial growth in the pharmaceutical industry; this is evident from the growing pipeline of drugs that are either approved or being investigated in different preclinical studies/clinical trials. However, poor water solubility and bioavailability are longstanding challenges in the drug development process. Around 90% of the drug candidates in the current development pipeline and close to 40% of the marketed pharmacological products are associated with concerns related to solubility and / or permeability. These poorly soluble drugs tend to get eliminated from the body (before their absorption into the systemic circulation), impacting their therapeutic effectiveness. Therefore, pharmaceutical companies are actively looking for strategies to overcome this challenge. Amongst the various approaches for enhancing solubility / bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and other lipidic excipients have garnered significant interest of drug developers. In addition, LNPs are known to be a versatile nanomedicine delivery platform owing to their ability to encapsulate a wide range of molecules and provide controlled drug release. Given the extensive research activity in this industry, the intellectual capital related to the use of LNPs in drug delivery has also grown over time.

However, lipid nanoparticle manufacturing is a cost-intensive and complex process that requires multidisciplinary expertise. Consequently, drug developers are increasingly relying on contract manufacturing organizations (CMOs) with specialized equipment and expertise to deal with the technical and routine operations-related challenges. Further, contracting a service provider enables sponsors to leverage innovative and advanced LNP technology (available with the service provider) and achieve greater operational flexibility. Owing to the inherent properties of LNPs, such as small size, multifunctional behavior and surface functionalization, the market for LNP-based therapeutics is likely to grow, in the foreseen future. This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Market Insights

The Lipid Nanoparticle Manufacturing Market: Services and Technologies, 2023-2035 - Distribution by Type of Lipid Nanoparticle (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers), Type of Molecule Delivered (Nucleic Acids, Small Molecules, Proteins/Peptides and Others), Company Size (Very Large and Large, Mid-sized and Small), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Blood Disorders, Rare Diseases and Other Disorders), Type of End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Other End-users) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.

Multifaceted Benefits of Lipid Nanoparticles

LNPs are transforming the field of nanomedicines with their ability to encapsulate and effectively deliver promising therapeutics (including small molecules and biologics) and vaccines into the body. In August 2018, the US Food and Drug Administration (US FDA) approved the first LNP based genomic medicine, Onpattro (developed by Alnylam) for the treatment of peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis in adult patients. These delivery systems protect the encapsulated (fragile) materials from degradation, maintain their integrity during transport and facilitate targeted release in specific areas. Notably, in the past few years, the clinical trials evaluating lipid nanoparticle mRNA-based therapeutics have increased due to their enhanced therapeutic effectiveness and low toxicity.

Use of Lipid Nanoparticles for mRNA Vaccine Delivery during the COVID19 Pandemic

Lipid nanoparticles played a significant role during the COVID vaccine development by serving as a delivery platform for mRNA vaccines. Some examples of companies that used LNPs in the development of COVID vaccines include (arranged in alphabetical order) AstraZeneca-Oxford University (ChAdOx1 nCoV-19), CanSino Biologicals (Ad5-nCoV), Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2/COMIRNATY). It is worth mentioning that the COVID vaccine developed by BioNTech-Pfizer and Moderna demonstrated a preventive efficiency of about 95%, and were the first mRNA vaccines to receive Emergency Use Authorization by the US FDA as well as European Medicines Agency (EMA), in December 2020 and January 2020, respectively.

Competitive Landscape of Lipid Nanoparticles Manufacturer

The current market landscape features the presence of around 45 lipid nanoparticle contract manufacturers, spread across the globe. Overall, the market seems to be well-fragmented, featuring the presence of very large, large, mid-sized and small companies, which have the required expertise to offer LNP manufacturing services (across different scales of operation). Majority (60%) of the facilities manufacture LNPs for encapsulating and delivering different types of nucleic acids, such as messenger RNA (mRNA), small interfering RNA (siRNA), deoxyribonucleic acid (DNA), self-amplifying RNA (saRNA) and micro-RNA (miRNA). Examples of some key lipid nanoparticle manufacturers include (which have been profiled in the report) BIOVECTRA, Curapath, Curia, Emergent BioSolutions, EUROAPI, Evonik and Precision NanoSystems.

LNP Technology Developers Landscape

Presently, more than 30 companies are engaged in the development of LNP technology; these companies operate through different business models, including fee-for-service / collaborative research, in-house product catalog and technology / product licensing. It is worth mentioning that most (93%) of the LNP technologies support the delivery of formulations through injectable route; some examples of such technologies include GalNAc-LNP (developed by Verve Therapeutics), ONCOPREX Nanoparticle Delivery System (developed by Genprex) and ScaffoLD Lipid Technology (developed by Integrated Nanotherapeutics). Further, the companies engaged in developing LNP technology include (which have been profiled in the market report) Acuitas Therapeutics, Ascendia Pharmaceuticals, Integrated Nanotherapeutics, leon-nanodrugs, Matinas BioPharma, Pantherna Therapeutics and TLC Biosciences.

Competitive Landscape of Lipid CMO

The current market landscape features the presence of over 55 companies involved in other types of lipid manufacturing, including ionizable lipids, liposomes, neural lipids, PEGylated lipids, phospholipids, sphingolipids and triglycerides. Further, over 80% of the facilities manufacturing other types of lipids offer formulation development services, followed by those providing process development / pre-formulation services (65%) and analytical method development (60%). Some examples of prominent players engaged in manufacturing other types of lipids include (which have been profiled in the market report) Avanti Polar Lipids, CordenPharma, Creative Biolabs, Formumax Scientific, Fresenius Kabi, Fujifilm and Merck.

Market Trends: Partnerships and Collaborations on the Rise for Lipid Nanoparticle Manufacturing

In recent years, several partnerships have been established by industry stakeholders, in order to consolidate their presence in this field, and enhance their capabilities and product portfolio to meet the growing demand for LNP-based drugs. It is worth highlighting that over 50% of these partnerships have been inked in the past two years. Interestingly, most of the agreements were research and development agreements, followed by product / technology licensing agreements and product development agreements. In April 2023, Moderna entered into an agreement with IBM in order to explore cutting-edge technologies, including quantum computing and artificial intelligence model (MoLFormer) to optimize LNPs and propel mRNA therapeutics research. In March 2023, Acuitas Therapeutics signed a licensing agreement with Athebio for the latter company’s Athebody® DARPin technology. The partnership aims to combine this technology with Acuitas’ LNP technology to enable targeted delivery of nucleic acid therapeutics. Such partnerships will foster the increase in application of LNP technology to support the delivery of novel drugs, increasing the demand for lipid nanoparticle manufacturing during the forecast period of this market report.

Market Analysis: Global Lipid Nanoparticle Manufacturing Market Size

The global lipid nanoparticle manufacturing market is estimated to be worth USD 0.66 billion in 2023. Driven by the increasing need for novel LNP formulation, along with the ongoing advancements in the LNP technology, the lipid nanoparticle manufacturing market is anticipated to grow at a CAGR of 11.8% during the forecast period. Additionally, in terms of type of LNP, the LNP manufacturing market is currently dominated by the revenues generated by solid lipid nanoparticles.

Regional Analysis: North America to Hold the Largest Share in Lipid Nanoparticles Market

Majority of the companies offering lipid nanoparticle manufacturing services are headquartered in North America, followed by companies based in Europe. Consequently, more than 40% of the global market for lipid nanoparticle manufacturing is anticipated to be captured by companies based in North America, in 2035.

Market Segment Analysis: Within Nucleic Acids Segment, mRNA Vaccines to Drive Market Growth

The research and development efforts being undertaken in the mRNA vaccines domain have evolved substantially over time, owing to their various advantages, including higher biological efficacy, enhanced immunogenicity and versatile vaccine delivery platforms, over other therapeutic modalities. Recent reports highlight the potential benefits of mRNA; for instance, no undesirable risk of inadvertent infection and insertional mutagenesis. In February 2022, Merck acquired Exelead, a CDMO capable of lipid nanoparticle manufacturing; through the acquisition, the company aims to enhance its capabilities and accelerate innovation in the mRNA vaccine domain. Further, in the same month, Curia acquired LakePharma and Integrity Bio to offer comprehensive mRNA based solutions to its clients.

In addition to linear mRNA, circular RNA (circRNA) and self-amplifying RNA (saRNA) vaccine platforms are now being acknowledged by the researchers. Owing to its closed-ring structure, circRNA demonstrates enhanced biostability and resistance towards exonuclease-mediated degradation, when compared to linear RNA. Further, saRNA facilitate large production of antigens (at low doses) and triggers an extensive immune response. As such, mRNA vaccines and mRNA therapeutics, along with other novel RNA therapeutics like circRNA and saRNA will drive the market growth for lipid nanoparticle manufacturing market during the forecast period.

Technological Development Analysis: Continuous Manufacturing and Adoption of Single Use Technology

The production of mRNA-LNP based drugs using the conventional batch processes is associated with certain challenges, due to the sensitive nature of mRNA and requirement of strict control over nanoparticle formation. As a result, drug developers are slowly transitioning from batch processing to continuous manufacturing. The continuous manufacturing process for such drugs offers various benefits, including consistent product quality, enhanced process efficiency, reduced production time, and real-time monitoring of the process parameters. As a result, DIANT Pharma has developed LNP encapsulated oligonucleotides using the continuous manufacturing process.

Further, single use technology has garnered the interest of various companies for both small scale and large scale production of LNP-based formulations; for instance, in July 2023 Precision NanoSystems (a part of Cytiva) launched single use NanoAssemblr® system that supports clinical and commercial manufacturing of lipid nanoparticles. The single use fluid path offers controlled mixing conditions, decreases the chances of cross-contamination and enables smooth changeover between batches.

Recent Developments in Lipid Nanoparticle Manufacturing Market

Several recent developments have taken place in the field of lipid nanoparticle manufacturing to advance efficient drug delivery, some of which have been outlined below. These developments, even if they took place after the release of this report, reflect the overall market trends that have been outlined in the analysis.

  • In October 2023, BIOVECTRA entered into a technology transfer service agreement with Acuitas Therapeutics to use the latter company’s LNP technology in manufacturing mRNA-based therapeutics.
  • In August 2023, Avanti Polar Lipids entered into a partnership with Bioz to identify relevant knowledge of products and techniques, in order to drive efficient research and development of novel lipid-based products.
  • In August 2023, a research study involving mRNA loaded LNPs showed promising results in reprogramming cells and editing the genes, in sickle cell disease.
  • In June 2023, Cardiff University in collaboration with Astra Zeneca used artificial intelligence generated LNPs to accurately target the diseased cells.
  • In July 2023, McGill University entered into a partnership with ModernaTX to evaluate the characteristics (including size and payload distribution) of LNPs; the outcome of the project is likely to support in the optimization of LNP manufacturing process and serve as a quality check during the manufacturing of mRNA-based therapeutics.
  • In March 2023, Moderna and Generation Bio signed an agreement to combine the former company’s biological and technical expertise with the latter company’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system.
  • In March 2023, the researchers at Hokkaido University encapsulated CRISPR-Cas9 with LNPs to evaluate its efficiency in preclinical models.
  • In February 2023, CordenPharma claimed to start operations in its newly set up GMP LNP suite, in Caponago, Italy facility by the third quarter of 2023; the expansion aims to support the rising demand of LNP-based therapeutics (clinical and commercial manufacturing).
  • In September 2022, WuXi STA, a China-based CRDMO, opened a new LNP formulation development and manufacturing facility to expand its end-to-end parenteral formulation capabilities for the development of complex injectables.

Scope of the Report

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in lipid nanoparticle manufacturing, across different geographies. Amongst other elements, the market report includes:

  • A preface providing an introduction to the full report, Lipid Nanoparticle Manufacturing Market: Services and Technologies, 2023-2035.
  • An outline of the systematic research methodology adopted to conduct the study on lipid nanoparticle manufacturing market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
  • An overview of economic factors that impact the overall lipid nanoparticle manufacturing market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the insights captured during the research. It offers a high-level view on the current state of lipid nanoparticle manufacturing market and its likely evolution in the mid-long term.
  • A general overview of lipids and its different types. The chapter also provides information on LNP / lipid nanoparticles, highlighting its different types, advantages and applications in the pharmaceutical domain. Further, it discusses the various challenges associated with formulation of LNPs, as well as the growing need for outsourcing the manufacturing operations of such products.
  • A detailed assessment of the lipid nanoparticles manufacturer, based on several relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), location of manufacturing facility, scale of operation (preclinical, clinical and commercial), type of molecule delivered (nucleic acids, proteins/peptides, small molecules and others), therapeutic area (infectious diseases, oncological disorders, rare diseases and others) and type of additional services offered (process development/pre-formulation, formulation development, analytical testing, stability studies, scale-up, regulatory support, fill/finish and packaging).
  • A detailed assessment of the lipid nanoparticle technology developers, based on several relevant parameters, such as type of formulation method (microfluidization, homogenization and others), type of molecule delivered (nucleic acids, proteins / peptides, small molecules and others), compatible dosage form (solid and liquid), route of administration (injectable, nasal, oral, topical and others), therapeutic area (oncological disorders, infectious diseases, genetic disorders, cardiovascular disorders, neurological disorders, metabolic disorders, ophthalmological disorders, autoimmune disorders and others). Further, the chapter provides information on the lipid nanoparticle technology developers, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), business model (in-house product catalog/pipeline, technology / product licensing, and fee-for-service / collaborative research) and most active players (in terms of number of technologies developed).
  • A detailed review of the lipid contract manufacturing companies, based on several relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), location of manufacturing facilities, scale of operation (preclinical, clinical and commercial), type of lipid manufactured (liposomes, phospholipids, PEGylated lipids, ionizable lipids, triglycerides, sphingolipids, neutral lipids and others), type of product (lipid-based FDF, lipid-based drug delivery system, lipid excipients and lipid-based API) and type of additional services offered (formulation development, process development/pre-formulation, analytical method development, scale-up, stability studies, regulatory support, fill/finish and packaging and other services).
  • A detailed competitiveness analysis of lipid nanoparticle contract manufacturing organizations based on company strength (in terms of years of experience), service strength (in terms of scale of operation, number of type of molecule delivered and number of additional services offered) and number of LNP manufacturing facilities.
  • An insightful competitiveness analysis of LNP technology based on developer strength (in terms of the experience, company size and business model of the developer), technology strength (in terms of number of route of administration, number of type of molecule delivered and number of compatible dosage form) and technology applicability (in terms of therapeutic area).
  • Elaborate profiles of prominent players (shortlisted based on our proprietary criterion) engaged in offering LNP manufacturing services and LNP technology. Each profile features a brief overview of the company (including information on year of establishment, location of headquarters, number of employees and leadership team), details related to its LNP service / technology portfolio, recent developments and an informed future outlook. In addition, the report also includes detailed profiles of other types of lipid CMO.
  • A detailed analysis of the partnerships inked between stakeholders engaged in this industry, since 2019, based on several parameters, such as year of partnership, type of partnership, type of molecule, therapeutic area, type of partner and the most active players (in terms of the number of partnerships signed). It also provides the regional distribution of the companies involved in these agreements.
  • An in-depth analysis of mRNA vaccines and therapeutics developers that are likely to partner with lipid nanoparticle manufacturer. These players have been shortlisted based on several relevant parameters, such as developer score (which takes into account a company’s size and experience in this field), pipeline strength (which takes into account the number of mRNA drugs in pipeline), as well as other mRNA drug related capabilities (which takes into account the target therapeutic area, route of administration and type of candidate).
  • An insightful make versus buy framework, highlighting the key indicators / factors that influence the decision of companies (referred to as sponsors in subsequent sections), whether to outsource the LNP manufacturing operations or develop the means to carry it in-house.
  • An estimate of the current global installed capacity available with various LNP contract manufacturers. The study further highlights the distribution of the global installed LNP contract manufacturing capacity, based on company size (small, mid-sized, and large and very large companies), scale of operation (preclinical, clinical and commercial) and geography (North America, Europe and Asia-Pacific).
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

The primary objectives of this market report are to furnish a comprehensive market forecast for estimating both the current market size and future opportunities in the lipid nanoparticle manufacturing market throughout the forecast period. Informed estimates have been presented regarding the anticipated evolution of market size from 2023 to 2035. Year-wise projections for current and future opportunities have been further categorized based on relevant parameters. These parameters include the type of lipid nanoparticle (solid lipid nanoparticles and nanostructured lipid carriers), type of molecule delivered (nucleic acids, small molecules, proteins/peptides, and others), company size (very large and large, mid-sized and small), target therapeutic area (infectious diseases, oncological disorders, blood disorders, rare diseases, and other disorders), type of end-user (pharmaceutical and biotechnology companies, academic and research institutes, and other end-users), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). To address future uncertainties associated with key parameters and enhance the robustness of the model, three market forecast scenarios, namely conservative, base, and optimistic scenarios, have been provided, representing different trajectories of the industry's evolution.

The opinions and insights conveyed in the market report were shaped by discussions with senior stakeholders in the industry. The report includes detailed transcripts of interviews conducted with key industry stakeholders.

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Key Companies Profiled

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Lipids
5.3 Introduction to Lipid Nanoparticles
5.3.1. Types of Lipid Nanoparticles
5.3.1.1. Solid Lipid Nanoparticles
5.3.1.2. Nanostructured Lipid Carriers
5.3.2. Advantages of Lipid Nanoparticles
5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
5.3.3.1. Cancer Treatment
5.3.3.2. Gene Therapy
5.3.3.3. Vaccine Development
5.3.3.4. Medical Imaging / Diagnostics
5.3.3.5. Additional Applications
5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
5.6. Concluding Remarks
6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
6.2.1 Analysis by Year of Establishment
6.2.2 Analysis by Company Size
6.2.3 Analysis by Location of Headquarters
6.2.4 Analysis by Company Size and Location of Headquarters
6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
6.2.6 Analysis by Scale of Operation
6.2.7 Analysis by Type of Molecule Delivered
6.2.8 Analysis by Therapeutic Area
6.2.9 Analysis by Type of Additional Services Offered
7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE
7.1. Chapter Overview
7.2. Lipid Nanoparticle: Technology Landscape
7.2.1. Analysis by Type of Formulation Method
7.2.2. Analysis by Type of Molecule Delivered
7.2.3. Analysis by Compatible Dosage Form
7.2.4. Analysis by Routes of Administration
7.2.5. Analysis by Therapeutic Area
7.3. Lipid Nanoparticle Technologies: List of Technology Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Business Model
7.3.6. Most Active Players: Analysis by Number of Technologies
8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE
8.1. Chapter Overview
8.2. Other Types of Lipids: List of Service Providers
8.2.1 Analysis by Year of Establishment
8.2.2 Analysis by Company Size
8.2.3 Analysis by Location of Headquarters
8.2.4 Analysis by Company Size and Location of Headquarters
8.2.5. Analysis by Location of Manufacturing Facility
8.2.6. Analysis by Scale of Operation
8.2.7 Analysis by Type of Lipid Manufactured
8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
8.2.9. Analysis by Type of Product
8.2.10. Analysis by Type of Additional Services Offered
8.2.11. Analysis by Type of Product and Type of Additional Services Offered
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
9.4.1. Company Competitiveness Analysis: Small Players
9.4.2. Company Competitiveness Analysis : Mid-sized Players
9.4.3. Company Competitiveness Analysis : Large and Very Large Players
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Players based in North America
10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific
11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES
11.1. Chapter Overview
11.2. Curia
11.2.1. Company Overview
11.2.2. Service Portfolio
11.2.3. Recent Developments and Future Outlook
11.3. Emergent BioSolutions
11.3.1. Company Overview
11.3.2. Service Portfolio
11.3.3. Recent Developments and Future Outlook
11.4. EUROAPI
11.4.1. Company Overview
11.4.2. Service Portfolio
11.4.3. Recent Developments and Future Outlook
11.5. Evonik
11.5.1. Company Overview
11.5.2. Service Portfolio
11.5.3. Recent Developments and Future Outlook
11.6. Ardena
11.6.1. Company Overview
11.6.2. Service Portfolio
11.7. BIOVECTRA
117.1. Company Overview
11.7.2. Service Portfolio
11.8. Precision NanoSystems
11.8.1. Company Overview
11.8.2. Service Portfolio
12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS
12.1. Chapter Overview
12.2. Ascendia Pharmaceuticals
12.2.1. Company Overview
12.2.2. Lipid Nanoparticle Technology Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. leon-nanodrugs
12.3.1. Company Overview
12.3.2. Lipid Nanoparticle Technology Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Pantherna Therapeutics
12.4.1. Company Overview
12.4.2. Lipid Nanoparticle Technology Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. TLC Biosciences
12.5.1. Company Overview
12.5.2. Lipid Nanoparticle Technology Portfolio
12.5.3. Recent Developments and Future Outlook
12.6. Acuitas Therapeutics
12.6.1. Company Overview
12.6.2. Service Portfolio
12.7. Integrated Nanotherapeutics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.8. Matinas BioPharma
12.8.1. Company Overview
12.8.2. Service Portfolio
13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS
13.1. Chapter Overview
13.2. Avanti Polar Lipids
13.2.1. Company Overview
13.2.2. Service Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Corden Pharma
13.3.1. Company Overview
13.3.2. Service Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Fujifilm
13.4.1. Company Overview
13.4.2. Service Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Merck
13.5.1. Company Overview
13.5.2. Service Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. FormuMax Scientific
13.6.1. Company Overview
12.6.2. Service Portfolio
13.7. Creative Biolabs
13.7.1. Company Overview
13.7.2. Service Portfolio
13.8. Fresenius Kabi
13.8.1. Company Overview
13.8.2. Service Portfolio
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Molecule
14.3.5. Analysis by Therapeutic Area
14.3.6. Analysis by Type of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Geography
14.3.8.1. Intracontinental and Intercontinental Deals
14.3.8.2. International and Local Deals
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Methodology
15.2. mRNA Drug Developers: Potential Strategic Partners in North America
15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
16. MAKE VERSUS BUY DECISION FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
16.3.1. Scenario 1
16.3.2. Scenario 2
16.3.3. Scenario 3
16.3.4. Scenario 4
16.4. Concluding Remarks
17. CAPACITY ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
17.3.1. Analysis by Range of Installed Capacity
17.3.2. Analysis by Company Size
17.3.3. Analysis by Scale of Operation
17.3.4. Analysis by Location of Manufacturing Facility
17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
17.3.5. Concluding Remarks
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion
19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Data Triangulation and Validation
21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Data Triangulation and Validation
22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Data Triangulation and Validation
23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.4. Data Triangulation and Validation
24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.4. Data Triangulation and Validation
25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. CONCLUSION
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. LIPOSOMA
27.2.1. Company Snapshot
27.3. BIOVECTRA
27.3.1. Company Snapshot
27.4. OZ Biosciences
27.4.1. Company Snapshot
28. APPENDIX 1: TABULATED DATA29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
LIST OF FIGURES
Figure 2.1. Research Methodology: Research Assumptions
Figure 2.2. Research Methodology: Project Methodology
Figure 2.3. Research Methodology: Forecast Methodology
Figure 2.4. Research Methodology: Robust Quality Control
Figure 2.5. Research Methodology: Key Market Segmentations
Figure 4.1. Executive Summary: Lipid Nanoparticle Manufacturing Service Providers Market Landscape
Figure 4.2. Executive Summary: Lipid Nanoparticle Technology Developers Market Landscape
Figure 4.3. Executive Summary: Service Providers of Other Types of Lipids Market Landscape
Figure 4.4. Executive Summary: Partnership and Collaborations
Figure 4.5. Executive Summary: Capacity Analysis
Figure 4.6. Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1. Classification of Lipids
Figure 5.2. Historical Development of Lipid Nanoparticles
Figure 5.3. Orientation of Drug in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers
Figure 5.4. Commonly Outsourced Lipid Nanoparticles Contract Manufacturing Services
Figure 6.1. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Year of Establishment
Figure 6.2. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size
Figure 6.3. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 6.4. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Figure 6.5. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Lipid Nanoparticle Manufacturing Facility
Figure 6.6. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Scale of Operation
Figure 6.7. Lipid Nanoparticles Manufacturing Service Providers: Distribution by Type of Molecule Delivered
Figure 6.8. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Therapeutic Area
Figure 6.9. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Figure 7.1. Lipid Nanoparticle Technologies: Distribution by Type of Formulation Method
Figure 7.2. Lipid Nanoparticle Technologies: Distribution by Type of Molecule Delivered
Figure 7.3. Lipid Nanoparticle Technologies: Distribution by Compatible Dosage Form
Figure 7.4. Lipid Nanoparticle Technologies: Distribution by Route of Administration
Figure 7.5. Lipid Nanoparticle Technologies: Distribution by Therapeutic Area
Figure 7.6. Lipid Nanoparticle Technology Developers: Distribution by Year of Establishment
Figure 7.7. Lipid Nanoparticle Technology Developers: Distribution by Company Size
Figure 7.8. Lipid Nanoparticle Technology Developers: Distribution by Location of Headquarters
Figure 7.9. Lipid Nanoparticle Technology Developers: Distribution by Company Size and Location of Headquarters
Figure 7.10. Lipid Nanoparticle Technology Developers: Distribution by Business Model
Figure 7.11. Most Active Players: Distribution by Number of Technologies
Figure 8.1. Service Providers of Other Types of Lipids: Distribution by Year of Establishment
Figure 8.2. Service Providers of Other Types of Lipids: Distribution by Company Size
Figure 8.3. Service Providers of Other Types of Lipids: Distribution by Location of Headquarters
Figure 8.4. Service Providers of Other Types of Lipids: Distribution by Company Size and Location of Headquarters
Figure 8.5. Service Providers of Other Types of Lipids: Distribution by Location of Manufacturing Facility
Figure 8.6. Service Providers of Other Types of Lipids: Distribution by Scale of Operation
Figure 8.7. Service Providers of Other Types of Lipids: Distribution by Type of Lipid Manufactured
Figure 8.8. Service Providers of Other Types of Lipids: Distribution by Scale of Operation and Type of Lipid Manufactured
Figure 8.9. Service Providers of Other Types of Lipids: Distribution by Type of Product
Figure 8.10. Service Providers of Other Types of Lipids: Distribution by Type of Additional Services Offered
Figure 8.11. Service Providers of Other Types of Lipids: Distribution by Type of Product and Type of Additional Services Offered
Figure 9.1. Company Competitiveness Analysis: Small Players
Figure 9.2. Company Competitiveness Analysis: Mid-sized Players
Figure 9.3. Company Competitiveness Analysis: Large and Very Large Players
Figure 10.1. Technology Competitiveness Analysis: Lipid Nanoparticle Manufacturing Technologies Offered by Players based in North America
Figure 10.2. Technology Competitiveness Analysis: Lipid Nanoparticle Manufacturing Technologies Offered by Players based in Europe and Asia-Pacific
Figure 14.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 14.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 14.4. Partnerships and Collaborations: Distribution by Type of Molecule
Figure 14.5. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 14.6. Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.7. Most Active Players: Distribution by Number of Partnerships
Figure 14.8. Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 14.9. Partnerships and Collaborations: International and Local Deals
Figure 15.1. Spider-web Analysis: Potential Strategic Partners in North America
Figure 15.2. Spider-web Analysis: Potential Strategic Partners in Europe and Asia-Pacific
Figure 16.1. Make versus Buy Decision Making Framework
Figure 16.2. Make versus Buy Decision Making: Possible Scenarios
Figure 17.1. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
Figure 17.2. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Company Size
Figure 17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 17.4. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 17.5. Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
Figure 17.6. Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
Figure 17.7. Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
Figure 18.1. Market Drivers
Figure 18.2. Market Restraints
Figure 18.3. Market Opportunities
Figure 18.4. Market Challenges
Figure 19.1. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.2. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Conservative Scenario (USD Billion)
Figure 19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Optimistic Scenario (USD Billion)
Figure 20.1. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2018, 2023 and 2035
Figure 20.2. Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 20.3. Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.1. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
Figure 21.2. Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.3. Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.4. Lipid Nanoparticle Manufacturing Market for Proteins/Peptides, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.5. Lipid Nanoparticle Manufacturing Market for Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 22.1. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
Figure 22.2. Lipid Nanoparticle Manufacturing Market for Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 22.3. Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates 2023-2035) (USD Billion)
Figure 22.4. Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 23.1. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
Figure 23.2. Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 23.3. Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 23.4. Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 23.5. Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 23.6. Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.1. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
Figure 24.2. Lipid Nanoparticle Manufacturing Market for Very Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.3. Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates 2023-2035) (USD Billion)
Figure 24.4. Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 25.1. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
Figure 25.2. Lipid Nanoparticle Manufacturing Market for North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 25.3. Lipid Nanoparticle Manufacturing Market for Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) Drivers and Restraints
Figure 25.4. Lipid Nanoparticle Manufacturing Market for Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 25.5. Lipid Nanoparticle Manufacturing Market for Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 26.1. Concluding Remarks: Lipid Nanoparticle Manufacturing Service Providers Market Landscape
Figure 26.2. Concluding Remarks: Lipid Nanoparticle Technology Developers Market Landscape
Figure 26.3. Concluding Remarks: Service Providers of Other Types of Lipids Market Landscape
Figure 26.4. Concluding Remarks: Partnerships and Collaborations
Figure 26.5. Concluding Remarks: Capacity Analysis
Figure 26.6. Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 26.7. Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
LIST OF TABLES
Table 6.1. Lipid Nanoparticle Manufacturing: List of Service Providers
Table 6.2. Lipid Nanoparticle Manufacturing Service Providers: Information on Scale of Operation and Type of Molecule Delivered
Table 6.3. Lipid Nanoparticle Manufacturing Service Providers: Information on Therapeutic Area and Additional Services Offered
Table 7.1. Lipid Nanoparticle Technologies: Information on Formulation Method and Type of Molecule Delivered
Table 7.2. Lipid Nanoparticle Technologies: Information on Compatible Dosage Form and Routes of Administration
Table 7.3. Lipid Nanoparticle Technologies: Information on Therapeutic Area
Table 7.4. Lipid Nanoparticle Technologies: List of Technology Developers
Table 8.1. Other Types of Lipids: List of Service Providers
Table 8.2. Service Providers of Other Types of Lipids: Information on Scale of Operation and Type of Lipid Manufactured
Table 8.3. Service Providers of Other Types of Lipids: Information on Type of Product and Additional Services Offered
Table 11.1. Leading Service Providers of Lipid Nanoparticles: List of Companies Profiled
Table 11.2. Curia: Company Snapshot
Table 11.3. Curia: Manufacturing Service Portfolio for LNPs
Table 11.4. Curia: Recent Developments and Future Outlook
Table 11.5. Emergent BioSolutions: Company Snapshot
Table 11.6. Emergent BioSolutions: Manufacturing Service Portfolio for LNPs
Table 11.7. Emergent BioSolutions: Recent Developments and Future Outlook
Table 11.8. EUROAPI: Company Snapshot
Table 11.9. EUROAPI: Manufacturing Service Portfolio for LNPs
Table 11.10. EUROAPI: Recent Developments and Future Outlook
Table 11.11. Evonik: Company Snapshot
Table 11.12. Evonik: Manufacturing Service Portfolio for LNPs
Table 11.13. BIOVECTRA: Company Snapshot
Table 11.14. BIOVECTRA: Manufacturing Service Portfolio for LNPs
Table 11.15. Curapath: Company Snapshot
Table 11.16. Curapath: Manufacturing Service Portfolio for LNPs
Table 11.17. Precision NanoSystems: Company Snapshot
Table 11.18. Precision NanoSystems: Manufacturing Service Portfolio for LNPs
Table 12.1. Leading LNP Technology Providers: List of Companies Profiled
Table 12.2. Ascendia Pharmaceuticals: Company Snapshot
Table 12.3. Ascendia Pharmaceuticals: Lipid Nanoparticle Technology Portfolio
Table 12.4. Ascendia Pharmaceuticals: Recent Developments and Future Outlook
Table 12.5. leon-nanodrugs: Company Snapshot
Table 12.6. leon-nanodrugs: Lipid Nanoparticle Technology Portfolio
Table 12.7. leon-nanodrugs: Recent Developments and Future Outlook
Table 12.8. Pantherna Therapeutics: Company Snapshot
Table 12.9. Pantherna Therapeutics: Lipid Nanoparticle Technology Portfolio
Table 12.10. Pantherna Therapeutics: Recent Developments and Future Outlook
Table 12.11. TLC Biosciences: Company Snapshot
Table 12.12. TLC Biosciences: Lipid Nanoparticle Technology Portfolio
Table 12.13. TLC Biosciences: Recent Developments and Future Outlook
Table 12.14. Acuitas Therapeutics: Company Snapshot Portfolio
Table 12.15. Acuitas Therapeutics: Lipid Nanoparticle Technology
Table 12.16. Integrated Nanotherapeutics: Company Snapshot
Table 12.17. Integrated Nanotherapeutics: Lipid Nanoparticle Technology Portfolio
Table 12.18. Matinas BioPharma: Company Snapshot
Table 12.19. Matinas BioPharma: Lipid Nanoparticle Technology Portfolio
Table 13.1. Leading Service Providers of Other Types of Lipids: List of Companies Profiled
Table 13.2. Avanti Polar Lipids: Company Snapshot
Table 13.3. Avanti Polar Lipids: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.4. CordenPharma: Company Snapshot
Table 13.5. CordenPharma: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.6. CordenPharma: Recent Developments and Future Outlook
Table 13.7. FUJIFILM: Company Snapshot
Table 13.8. FUJIFILM: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.9. FUJIFILM: Recent Developments and Future Outlook
Table 13.10. Merck: Company Snapshot
Table 13.11. Merck: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.12. Merck: Recent Developments and Future Outlook
Table 13.13. FormuMax Scientific: Company Snapshot
Table 13.14. FormuMax Scientific: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.15. Creative Biolabs: Company Snapshot
Table 13.16. Creative Biolabs: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.17. Fresenius Kabi: Company Snapshot
Table 13.18. Fresenius Kabi: Manufacturing Service Portfolio for Other Types of Lipids
Table 14.1. Lipid Nanoparticle Services and Technologies: List of Partnerships and Collaborations, 2019-2023
Table 15.1. mRNA Drug Developers: Potential Strategic Partners in North America
Table 15.2. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
Table 17.1. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Average Capacity by Company Size (Sample Dataset)
Table 17.2. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Total Capacity by Company Size (Liters)
Table 27.1. LIPOSOMA: Company Snapshot
Table 27.2. BIOVECTRA: Company Snapshot
Table 27.3. OZ Biosciences: Company Snapshot
Table 28.1. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Year of Establishment
Table 28.2. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size
Table 28.3. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Headquarters
Table 28.4. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Table 28.5. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Lipid Nanoparticle Manufacturing Facility
Table 28.6. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Scale of Operation
Table 28.7. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Molecule Delivered
Table 28.8. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Therapeutic Area
Table 28.9. Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Table 28.10. Lipid Nanoparticle Technologies: Distribution by Type of Formulation Method
Table 28.11. Lipid Nanoparticle Technologies: Distribution by Type of Molecule Delivered
Table 28.12. Lipid Nanoparticle Technologies: Distribution by Compatible Dosage Form
Table 28.13. Lipid Nanoparticle Technologies: Distribution by Route of Administration
Table 28.14. Lipid Nanoparticle Technologies: Distribution by Therapeutic Area
Table 28.15. Lipid Nanoparticle Technology Developers: Distribution by Year of Establishment
Table 28.16. Lipid Nanoparticle Technology Developers: Distribution by Company Size
Table 28.17. Lipid Nanoparticle Technology Developers: Distribution by Location of Headquarters
Table 28.18. Lipid Nanoparticle Technology Developers: Distribution by Company Size and Location of Headquarters
Table 28.19. Lipid Nanoparticle Technology Developers: Distribution by Business Model
Table 28.20. Most Active Players: Distribution by Number of Technologies
Table 28.21. Service Providers of Other Types of Lipids: Distribution by Year of Establishment
Table 28.22. Service Providers of Other Types of Lipids: Distribution by Company Size
Table 28.23. Service Providers of Other Types of Lipids: Distribution by Location of Headquarters
Table 28.24. Service Providers of Other Types of Lipids: Distribution by Company Size and Location of Headquarters
Table 28.25. Service Providers of Other Types of Lipids: Distribution by Location of Manufacturing Facility
Table 28.26. Service Providers of Other Types of Lipids: Distribution by Scale of Operation
Table 28.27. Service Providers of Other Types of Lipids: Distribution by Type of Lipid Manufactured
Table 28.28. Service Providers of Other Types of Lipids: Distribution by Scale of Operation and Type of Lipid Manufactured
Table 28.29. Service Providers of Other Types of Lipids: Distribution by Type of Product
Table 28.30. Service Providers of Other Types of Lipids: Distribution by Type of Additional Services Offered
Table 28.31. Service Providers of Other Types of Lipids: Distribution by Type of Product and Type of Services Offered
Table 28.32. Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 28.33. Partnerships and Collaborations: Distribution by Type of Partnership
Table 28.34. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 28.35. Partnerships and Collaborations: Distribution by Type of Molecule
Table 28.36. Partnerships and Collaborations: Distribution by Therapeutic Area
Table 28.37. Partnerships and Collaborations: Distribution by Type of Partner
Table 28.38. Most Active Players: Distribution by Number of Partnerships
Table 28.39. Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 28.40. Partnerships and Collaborations: International and Local Deals
Table 28.41 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
Table 28.42. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Company Size
Table 28.43. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 28.44. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Table 28.45. Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
Table 28.46. Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
Table 28.47. Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
Table 28.48. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.49. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Conservative Scenario (USD Billion)
Table 28.50. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Optimistic Scenario (USD Billion)
Table 28.51. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2018, 2023 and 2035
Table 28.52. Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.53. Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.54. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
Table 28.55. Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.56. Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.57. Lipid Nanoparticle Manufacturing Market for Proteins/Peptides, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.58. Lipid Nanoparticle Manufacturing Market for Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.59. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
Table 28.60. Lipid Nanoparticle Manufacturing Market for Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.61. Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates 2023-2035) (USD Billion)
Table 28.62. Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.63. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
Table 28.64. Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.65. Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.66. Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.67. Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.68. Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.69. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
Table 28.70. Lipid Nanoparticle Manufacturing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.71. Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates 2023-2035) (USD Billion)
Table 28.72. Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.73. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
Table 28.74. Lipid Nanoparticle Manufacturing Market for North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.75. Lipid Nanoparticle Manufacturing Market for Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) Drivers and Restraints
Table 28.76. Lipid Nanoparticle Manufacturing Market for Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 28.77. Lipid Nanoparticle Manufacturing Market for Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 2seventy bio
  • ABITEC
  • Acuitas Therapeutics
  • ADM
  • Afrigen Biologics
  • AIM Vaccine
  • Ajinomoto Bio-Pharma Services
  • Aragen Life Sciences
  • Arbor Biotechnologies
  • Arbutus Biopharma
  • Arcturus Therapeutics
  • Ardena
  • Arranta Bio
  • Ascendia Pharmaceuticals
  • Ascension Sciences
  • AskBio
  • Astellas Pharma
  • Athebio
  • Avanti Polar Lipids (Acquired by Croda International)
  • B. Braun
  • Baseimmune
  • BASF Pharma
  • Beam Therapeutics
  • BeiGene
  • Bio-Serv
  • BioNTech
  • Biopharma PEG Scientific
  • BIOVECTRA
  • BOC Sciences
  • BSP Pharmaceuticals
  • CanSino Biologics
  • Carisma Therapeutics
  • Catalent
  • Cayman Chemical
  • CD Bioparticles
  • Celonic
  • Cone Bioproducts
  • ConserV Bioscience 
  • CordenPharma
  • Creative Biolabs
  • Creative Biostructure
  • Croda 
  • CSL Seqirus
  • CSPC ZhongQi Pharmaceutical Technology
  • Curapath
  • CureVac
  • Curia
  • Cytiva
  • Daewoong Pharmaceutical
  • Daiichi Sankyo
  • Dalton Pharma Services
  • Danaher
  • DIANT Pharma
  • Dolomite Microfluidics (Acquired by Unchained Labs)
  • DSM
  • Emergent BioSolutions
  • Empirical Labs 
  • Encapsula NanoSciences
  • Endo International
  • Entos
  • Esco Aster
  • eTheRNA
  • EUROAPI
  • Evonik
  • Exelead (Acquired by Merck)
  • ExploRNA Therapeutics
  • ForDoz Pharma
  • FormuMax Scientific
  • Fresenius Kabi
  • Fujifilm 
  • Gattefossé 
  • GC Biopharma
  • Generation Bio
  • Genevant Sciences
  • Gennova (Subsidiary of Emcure Pharmaceuticals)
  • Genprex
  • Ghent University
  • GP Pharm
  • GreenLight Biosciences
  • Gritstone bio
  • Harro Höfliger
  • Helix Biotech
  • HTD Biosystems
  • Humboldt University of Berlin 
  • IBM
  • IMUNON 
  • InnoRNA
  • Integrated Nanotherapeutics
  • Integrity Bio (Acquired by Curia)
  • KD Pharma 
  • Kernal Biologics
  • Korro Bio
  • Lead Biotherapeutics
  • leon-nanodrugs
  • LGC Axolabs
  • Lipid Systems Sp.
  • Lipidome Lifesciences
  • Lipoid
  • LIPOSOMA
  • Lonza
  • Ludwig Maximilian University
  • Matinas BioPharma
  • Merck
  • Metagenomi
  • Micro-Sphere
  • Moderna
  • MyBiotech
  • Myeloid Therapeutics
  • Nabros Pharma
  • NanoVation Therapeutics
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Resilience
  • NeoVac
  • NextPharma
  • Nippon Fine Chemical 
  • NOF Corporation
  • Omega Therapeutics
  • Oncorus
  • Orna Therapeutics
  • OZ Biosciences 
  • Pantherna Therapeutics
  • Particle Works (Part of Unchained Labs)
  • PCI Pharma Services
  • PendreaBio (Formerly known as Keystone Nano)
  • Pfizer
  • Phosphorex
  • Piramal Pharma Solutions
  • Polymun Scientific
  • Precigenome
  • Precision NanoSystems
  • ProMab Biotechnologies
  • Providence Therapeutics
  • PROVIREX Genome Editing Therapies
  • Quay Pharma
  • QurCan Therapeutics
  • Recipharm
  • ReCode Therapeutics
  • Replicate Bioscience
  • Research Complex at Harwell 
  • Sanofi
  • Sarepta Therapeutics
  • SciTech Development
  • Shochem (Shanghai)
  • ST Pharm
  • STA Pharmaceutical
  • StaniPharm
  • Takeda Pharmaceutical
  • Tergus Pharma
  • TLC Biosciences
  • TTY Biopharm Company 
  • Turn Biotechnologies
  • University of Connecticut (UConn)
  • Valimenta Labs
  • VAV Life Sciences
  • Vaxinano
  • Vernal Biosciences
  • Vertex Pharmaceuticals
  • Verve Therapeutics
  • ViiV Healthcare
  • VLP Therapeutics
  • WuXi STA (A subsidiary of WuXi AppTec)
  • ZoneOne Pharma

Methodology

 

 

Loading
LOADING...

Table Information